Joe Mullings I Orthopedics Market Shifts
When a category transitions from mechanical precision to digital intelligence, the incumbent tool companies eventually […]
When a category transitions from mechanical precision to digital intelligence, the incumbent tool companies eventually lose to the digital-native.
It is gradual until it is sudden.
It is not because they lack resources or awareness, but it is due to fact that their organizational DNA was built to optimize for the prior paradigm.
In soft tissue surgery, Ethicon Endo-Surgery, Inc. and US Surgical / Medtronic defined minimally invasive surgery. They built the tools, trained the surgeons, established the workflows. When robotic-assisted surgery arrived, the challenge was who designs the best platform for the surgeon?
Intuitive had nothing to protect. Ethicon and Medtronic had everything to lose from cannibalizing their stapler and energy device franchises. Twenty years later, Intuitive currently owns the market and the late entrants are still closing gaps.
We are seeing a similar pattern unfold in orthopedic robotics. Stryker acquired Mako and coupled it to Triathlon. DePuy Synthes and Smith+Nephew built their own robots around their implant franchises. The logic was sound for a single cycle.
Use the robot as a pull-through vehicle for implant revenue and few could have forecast the existential structural problem that may have come calling. When your robot exists to protect your implant margins, you cannot build a genuinely open, data-first platform.
You cannot ask the unbiased questions about what works for which patient, nor can you accumulate the multi-implant, multi-surgeon, longitudinal outcome data that the next layer of the market will be built on. You are solving for the prior era’s competitive advantage while the market moves to the next one.
Recently, THINK Surgical just demonstrated what happens when a company is not encumbered by that constraint. They cleared the Stryker Triathlon knee independently, without Stryker’s cooperation. And remarkably caught them by surprise. (That’s another story for another time) Nine compatible implant options on one platform. The robot is agnostic about which implant succeeds.
Which means THINK is the only company generating unbiased intraoperative data across implant families, surgical techniques, and patient populations. That dataset is not a feature but a structural competitive advantage. It is what Intuitive built over 30 years in soft tissue. THINK is building it now in hard tissue, at scale, without the organizational permission structure that would prevent them from asking the obvious questions.
